- Teva Pharmaceutical Industries is undergoing a strategic shift towards branded drugs, leading to an 85% stock price increase over the past year.
- The company reported strong Q2 2026 revenues of $4.14 billion, surpassing analyst estimates, primarily driven by robust branded drug sales, including UZEDY® net sales of $77 million.
- Despite revenue growth, Teva's earnings per share (EPS) of $0.02 missed consensus, and the company faces financial considerations with a debt-to-equity ratio of 2.18 and a current ratio of 0.88.
Teva Pharmaceutical Industries (NYSE:TEVA) is a global pharmaceutical company that develops, produces, and markets both generic and branded medications. The company is undergoing a strategic shift, focusing more on its branded drugs like Austedo, Ajovy, and Uzedy. This change is impacting its financial performance and stock price, which has increased by approximately 85% over the last year.
On July 29, 2026, Teva reported its quarterly financial results. The company announced revenues of $4.14 billion for the period, which was higher than the analyst consensus estimate of $4.02 billion. This positive revenue result shows strength in the company's sales activities during the quarter.
A key driver of this revenue beat was the strong performance of its branded drug portfolio. As highlighted by Business Wire, U.S. net sales for its schizophrenia treatment, UZEDY®, reached a record $77 million. This represents a 43% increase compared to the same quarter last year. Following this, Teva raised its full-year revenue outlook for UZEDY®.
However, the company's earnings per share (EPS) came in at $0.02, falling short of the $0.08 consensus estimate. This aligns with guidance from management, which anticipates lower EPS for 2026. As reported by The Motley Fool, this is mainly due to the dilutive effect of a recent acquisition, which spreads earnings over more shares.
From a financial standpoint, Teva holds a debt-to-equity ratio of 2.18, indicating it uses more debt than equity to finance its assets. The company also has a current ratio of 0.88. This ratio measures a company's ability to pay its short-term obligations, with a value below 1 suggesting potential liquidity constraints.